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PULMONARY MEDICINE

Case Report of E-cigarette Associated Lung Injury
in a Healthy Female
Mario Fonseca-Paricio, MD, Alan Gandler, MD, Boyd Hehn, MD

CASE DESCRIPTION
This is a case of a woman presenting with four days of
diarrhea and dyspnea found to have E-cigarette or vapingassociated lung injury (EVALI).
The patient is a 30-year-old woman who presented to the
hospital with a chief complaint of dyspnea on exertion.
She developed dyspnea seven days prior to presentation;
it was minimal at rest, however symptoms worsened with
exertion. Her symptoms included fevers, intermittent
chills, night sweats, dry persistent cough, and four days of
profuse, watery diarrhea. She did not have sinus pain or
congestion, headaches, or sore throat. Due to bloody
diarrhea she sought medical care.
The patient had no allergies and took no medications
regularly. She had a history of exercised-induced asthma
during childhood that had resolved. Surgical history was
notable for seven surgeries for bilateral breast
fibroadenomas. Family history was notable for
BRCA-negative breast cancer in her mother.
She works as a real estate agent, with no known specific
exposures. Ten days prior to admission, she had spent
time with her nephew who she reported as having several
symptoms consistent with an upper respiratory infection.
She does not smoke cigarettes. She had been using
electronic cigarettes with marijuana for 6 months earlier
in the year, however due to news reports, she had recently
stopped. She would smoke marijuana from electronic
cigarettes four days a week with cartridges lasting about
one week. Patient used no other drugs or alcohol. No
history of homelessness or incarceration. Patient is
sexually active with one male partner with no prior HIV or
sexually transmitted infections (STI). On review of systems,
patient noted to have an unintentional 5-pound weight
loss over the past one week.
On initial vital signs, she had temperature of 38.2 C, HR of
117 bpm, blood pressure of 108/74 mmHg, respiratory
rate of 22 breaths/minute, 86% on ambient air and 95%
on 2 liters nasal cannula of oxygen. She was admitted to
the medical service due to a new oxygen requirement.
Physical exam was notable for of a well-developed and
nourished adult female in no acute distress on nasal
cannula able to speak in full sentences. Pulmonary exam
showed scattered rales with no wheezing. She had
tachycardia with no jugular venous distention. She had no
abdominal pain or lower extremity swelling.
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Figure 1. High-resolution CT of the chest demonstrating diffuse ground-glass
opacities with septal thickening. There is a peripheral predilection with
subpleural sparring disease.

Laboratory results on presentation revealed a leukocytosis
of 28,000 cells/mm3 with 92% neutrophils and a platelet
count of 558 cells/mm3. Electrolytes revealed a
potassium of 2.9 mEq/L, HCO3 of 22 mEq/L. Liver
function tests showed an AST/ALT of 119/73 IU/L. Lipase
was normal. Lactate normal at 1.2 mmol/L. Procalcitonin
was 0.64 ng/mL (normal < 0.08 ng/mL).
Respiratory pathogen panel nasopharynx swab detected
human rhinovirus/enterovirus on PCR. Blood cultures
showed no growth. Influenza A/B, RSV PCR nasal swab
was negative. Clostridium difficile toxin DNA, and gastrointestinal stool infectious panel were negative. HIV
antibody and antigen combination were non-reactive.
Streptococcus pneumoniae and Legionella antigen urine
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Figure 2. On the left, Romanowski stain showing numerous alveolar macrophages with abundant vacuolated cytoplasm. On the right, positive orangestained droplets within the cytoplasmic vacuoles of alveolar macrophages.

test were negative. Urine pregnancy test was negative.
Urine drug screen was positive for cannabinoid.
Chest x-ray on initial evaluation revealed diffuse patchy
bilateral opacities with no effusions. Right upper quadrant
ultrasound was normal.
Patient was admitted and placed on azithromycin and
ceftriaxone for community-acquired pneumonia.
Subsequently was changed to levofloxacin 750 mg oral.
Due to continued oxygen desaturation on ambient air,
intermittent fevers, and tachycardia for two-day duration
despite antibiotics and supportive care a high-resolution
computed topography (HRCT) of the chest was obtained.
HRCT demonstrated widespread ground glass opacities
and scattered septal thickening bilaterally without lobar
predominance, with diffuse subpleural sparing (Figure 1).
There were dense consolidations seen in the bilateral lobes
and the right middle lobe. These findings were consistent
with inhalation-induced lung injury as well as viral and
atypical pneumoniae.
Patient subsequently underwent bronchoscopy. Findings
notable for normal airway with parenchymal infiltrates.
Bronchoalveolar lavage (BAL) with a transbronchial biopsy
were performed. Right middle and left upper lobe BAL
pathology revealed oil-red O stain showing intracytoplasmic lipid droplets in alveolar macrophages consistent
with lipid laden-macrophages (Figure 2). Transbronchial
biopsy of the left lingula showed pneumonitis; there was
interstitial edema, inflammation, mild fibrosis, hyperplasia
of type II pneumocytes, organizing pneumonia, and
macrophages in the airspace.
The history, imaging and pathology were felt to be
consistent with EVALI. Due to this the patient was placed
on three days of methylprednisone 250 mg every 12
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hours. Upon the second day of this regimen, she no
longer had ambulatory desaturation with stable vital signs.
She finished a seven-day course of antibiotics while
hospitalized. She was discharged on 40 mg daily of
prednisone for with subsequent pulmonary medicine
outpatient visit, which has not yet occurred.

DISCUSSION
EVALI is lung injury due to the inhalation of non-combustible
aerosol containing “nicotine, flavors, propylene glycol, and
vegetable glycerin”, which includes battery operated
devices that include electronic cigarettes (e-cigarettes).1
EVALI is becoming a more prevalent, being formally
recognized in 2019, with over 2,000 cases reported in the
United States by the Center for Disease Control (CDC).2,3
This new clinical entity has led to interest in the
pathogenesis of EVALI. Though no single agent has been
implicated in the pathogenesis of EVALI, many patients
have used nicotine, tetrahydrocannabinol (THC), and
cannabinoid (CBD) oils.2,4 Another agent of interest
implicated in in the pathogenesis of EVALI is vitamin E
acetate, which has been associated with impairment of
pulmonary surfactant.5,6
EVALI is a type of acute lung-injury presenting with a
wide-range of pulmonary complaints and findings. The
most common presenting symptoms fevers, tachycardiac,
and tachypnea.4 One review revealed gastrointestinal
symptoms in about 80% of patients. In this same review,
67% of patients presented with hypoxemia, and about 30%
of patients had oxygen saturation less than 88%.4 Chest
imaging generally reveals marked bilateral opacities. The
typical chest CT finding is ground glass opacities marked
by subpleural sparing.4,7 These findings, however, can be
seen in other pathological process and thus may warrant
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further investigations with bronchoscopy and BAL. EVALI
leads to alveolar damage and fibrinous pneumonitis and
has a wide range of histopathological findings. Most
reported cases involve variation in cell counts from BAL,
though usually with a predominance of neutrophils.4 Many
cases report Oil-red-O staining lipid-laden macrophages
as in this patient.8
One confounding variable in this case was a positive
rhinovirus/enterovirus test, which could explain some of
her symptoms. However, it is unlikely that this viral infection
would have produced such significant clinical decompensation in an otherwise young and healthy patient. Moreover,
clinical history, ground glass opacities with subpleural
sparing, and lipid-laden macrophages with pneumonitis
are consistent with our current understanding of EVALI.

CONCLUSION
In patients who present with respiratory complaints and
history of E-cigarettes, EVALI should be strongly
considered. This is particularly true in those with
hypoxemia and respiratory distress. A chest CT is an
Important diagnostic modality to help identify and
inhalation pattern injury, but many patients may need
further testing with bronchoscopy and BAL. We presented
a case of a young, healthy patient who had significant
respiratory distress secondary to EVALI.
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